Canopy Growth (CGC) Cash from Restructuring (2020 - 2021)
Canopy Growth's (CGC) quarterly Cash from Restructuring came in at $72.6 million in Q2 2021, up 686.88% year-on-year from $9.2 million in Q2 2020, and up 22.82% quarter-over-quarter from $59.1 million in Q1 2021.
Canopy Growth (CGC) Cash from Restructuring (2020 - 2021) Analysis & Trends
Canopy Growth has disclosed Cash from Restructuring across 2 years of filings, most recently posting $72.6 million for Q2 2021.
- Cash from Restructuring for Q2 2021 came in at $72.6 million, up 686.88% year-over-year; the trailing twelve-month figure through Jun 2021 was $473.7 million (changed N/A YoY), and the FY2021 annual result was $422.2 million, down 9.18% from the prior year.
- Cash from Restructuring came in at $72.6 million for Q2 2021 at Canopy Growth, up from $59.1 million in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $307.1 million in Q4 2020 to a low of $9.2 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Canopy Growth | 11.38 Mn | -137.31 Mn | 15.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 72.61 Mn |
| Mar 31, 2021 | 59.11 Mn |
| Dec 31, 2020 | 307.15 Mn |
| Sep 30, 2020 | 34.79 Mn |
| Jun 30, 2020 | 9.23 Mn |